News stories about NxStage Medical (NASDAQ:NXTM) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NxStage Medical earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 45.2259325218986 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Several research analysts have weighed in on the company. Zacks Investment Research raised NxStage Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Northland Securities reissued a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a research report on Wednesday, November 8th. Finally, Canaccord Genuity reissued a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a research report on Tuesday, October 17th. One analyst has rated the stock with a sell rating and nine have issued a hold rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $30.25.
NxStage Medical (NXTM) opened at $24.49 on Tuesday. NxStage Medical has a 1 year low of $20.45 and a 1 year high of $30.80. The company has a market capitalization of $1,620.00, a price-to-earnings ratio of -116.62 and a beta of -0.08.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.